GALT Galectin Therapeutics

Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders

Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders

NORCROSS, Ga., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H. Shlevin, Ph.D., president and chief executive officer, will present a corporate update via live webcast immediately following the business portion of its 2019 Annual Meeting of Stockholders. The webcast is expected to commence at approximately 9:30 a.m. ET on Wednesday, December 4, 2019.

The webcast can be accessed via the investor relations portion of the Galectin Therapeutics website at . The presentation can be heard via teleconference by dialing 866-225-1342 (within the United States). A list of international dial-in numbers can be found . The passcode for participants is 2856445641.

Please log in approximately 10 minutes before the event to ensure a timely connection. You may also test your connection prior to the start of the presentation by visiting: . The webcast will be archived on the Company's website.

For stockholders in attendance, there will be a question and answer period following the presentation at which pre-submitted written questions will be answered. Questions must be submitted via email by end of the day on Monday, December 2, 2019, to . The Company will cover as many submitted questions as possible in the time allotted.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer.

Additional information is available at .

Company Contact:

Jack Callicutt, Chief Financial Officer

(678) 620-3186

Media Contact:

Gregory FCA

Rachel Giltz, Senior Account Executive

(215) 297-3607

EN
26/11/2019

Underlying

GALTGalectin Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galectin Therapeutics

 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin ...

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 10, 2026 at 12:00 PM ET. To register, The event will focus on ...

1h / 24m 1 EN
Free Trial
GALT Galectin Therap...

Galectin Therapeutics Inc: 3 directors

Three Directors at Galectin Therapeutics Inc sold after exercising options/sold 51,770 shares at between 7.038USD and 7.056USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades ...

GALT GALECTIN THERAPEUTICS
12/19/25 December 19, 2025 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Provides Regulatory Update Following FDA Written...

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company’s previously submitted Type C meeting request rega...

December 19, 2025 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Reports Financial Results for the quarter ended ...

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025. “The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers—including FibroScan®, ELF, and PRO-C3—all ...

November 14, 2025 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Presented NAVIGATE Trial Results at the American...

Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for clinically meaningful worsening, a lower proportion of patients treated with belapectin 2 mg/kg experienced ≥30% or ≥5 kPa increases in liver stiffness (LSM) by FibroScan® compared with placebo, indicating slowing of fibrosis progression and stabilization of liver functionAcross all ELF fibrosis risk categori...

November 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch